Design of an RCT on cost-effectiveness of group schema therapy versus individual schema therapy for patients with Cluster-C personality disorder: the QUEST-CLC study protocol

被引:8
作者
Groot, Iuno Z. [1 ]
Venhuizen, Anne-Sophie S. M. [1 ]
Bachrach, Nathan [2 ,3 ]
Walhout, Simone [3 ]
de Moor, Bregje [3 ]
Nikkels, Kasper [4 ]
Dalmeijer, Susanne [5 ]
Maarschalkerweerd, Myrte [6 ]
van Aalderen, Joel R. [7 ]
de Lange, Hinde [8 ]
Wichers, Renske [9 ]
Hollander, Agatha Ph. [10 ]
Evers, Silvia M. A. A. [11 ,12 ]
Grasman, Raoul P. P. P. [13 ]
Arntz, Arnoud [1 ]
机构
[1] Univ Amsterdam, Dept Clin Psychol, POB 15933, NL-1001 NK Amsterdam, Netherlands
[2] Tilburg Univ, Dept Med & Clin Psychol, Tilburg, Netherlands
[3] GGZ Oost Brabant, Dept Personal Disorders, Oss, Netherlands
[4] PsyQ Amsterdam, Amsterdam, Netherlands
[5] PsyQ Zaandam, Zaandam, Netherlands
[6] PsyQ Rotterdam, Rotterdam, Netherlands
[7] PsyQ Utrecht, Utrecht, Netherlands
[8] Emergis, Goes, Netherlands
[9] IPGGZ Veendam, Veendam, Netherlands
[10] IPGGZ Groningen, Groningen, Netherlands
[11] Maastricht Univ, Dept Hlth Serv Res, Care & Publ Hlth Res Inst CAPHRI, Maastricht, Netherlands
[12] Trimbos Inst, Ctr Econ Evaluat, Utrecht, Netherlands
[13] Univ Amsterdam, Dept Psychol Methods, Amsterdam, Netherlands
关键词
Cluster-C personality disorder; Randomized controlled trial; Group schema therapy; Individual schema therapy; Economic evaluation; Personalized care; AUTISM-SPECTRUM QUOTIENT; CONTROLLED-TRIAL; MENTAL-HEALTH; PSYCHOTHERAPY; MULTICENTER; PREVALENCE; VERSION; LIFE;
D O I
10.1186/s12888-022-04248-9
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: Given the high prevalence of Cluster-C Personality Disorders (PDs) in clinical populations, disease burden, high societal costs and poor prognosis of comorbid disorders, a major gain in health care can be achieved if Cluster-C PDs are adequately treated. The only controlled cost-effectiveness study published so far found Individual Schema Therapy (IST) to be superior to Treatment as Usual (TAU). Group ST (GST) might improve cost-effectiveness as larger numbers can be treated in (>50%) less time compared to IST. However, to date there is no RCT supporting its (cost-) effectiveness. The overall aim of this study is to assess the evidence for GST for Cluster-C PDs and to improve treatment allocation for individual patients. Three main questions are addressed: 1) Is GST for Cluster-C PDs (cost-) effective compared to TAU? 2) Is GST for Cluster-C PDs (cost-) effective compared to IST? 3) Which patient-characteristics predict better response to GST, IST, or TAU? Methods: In a multicenter RCT, the treatment conditions GST, IST, and TAU are compared in 378 Cluster-C PD patients within 10 sites. GST and IST follow treatment protocols and are completed within 1 year. TAU is the optimal alternative treatment available at the site according to regular procedures. Severity of the Cluster-C PD is the primary outcome, assessed with clinical interviews by independent raters blind for treatment. Functioning and wellbeing are important secondary outcomes. Assessments take place at week 0 (baseline), 17 (mid-GST), 34 (post-GST), 51 (post-booster sessions of GST), and 2 years (FU). Patient characteristics predicting better response to a specific treatment are studied, e.g., childhood trauma, autistic features, and introversion. A tool supporting patients and clinicians in matching treatment to patient will be developed. An economic evaluation investigates the cost-effectiveness and cost-utility from a societal perspective. A process evaluation by qualitative methods explores experiences of participants, loved ones and therapists regarding recovery, quality of life, and improving treatment. Discussion: This study will determine the (cost-)effectiveness of treatments for Cluster-C PDs regarding treatment type as well as optimal matching of patient to treatment and deliver insight into which aspects help Cluster-C-PD patients recover and create a fulfilling life.
引用
收藏
页数:18
相关论文
共 74 条
  • [1] Measuring happiness with a single-item scale
    Abdel-Khalek, AM
    [J]. SOCIAL BEHAVIOR AND PERSONALITY, 2006, 34 (02): : 139 - 149
  • [2] Toward Brief "Red Flags" for Autism Screening: The Short Autism Spectrum Quotient and the Short Quantitative Checklist in 1,000 Cases and 3,000 Controls
    Allison, Carrie
    Auyeung, Bonnie
    Baron-Cohen, Simon
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2012, 51 (02) : 202 - 212
  • [3] American Psychiatric Association, 2017, NEDERLANDSE VERTALIN
  • [4] [Anonymous], 2000, WHO DISABILITY ASSES
  • [5] Beliefs in personality disorders: a test with the personality disorder belief questionnaire
    Arntz, A
    Dreessen, L
    Schouten, E
    Weertman, A
    [J]. BEHAVIOUR RESEARCH AND THERAPY, 2004, 42 (10) : 1215 - 1225
  • [6] Arntz A., 2017, GROUP SCHEMA THERAPY
  • [7] Arntz A, 2021, INTROVERSION INVENTO
  • [8] Arntz A, 2012, WILEY BLACKWELL HDB, P397
  • [9] Effectiveness of Predominantly Group Schema Therapy and Combined Individual and Group Schema Therapy for Borderline Personality Disorder A Randomized Clinical Trial
    Arntz, Arnoud
    Jacob, Gitta A.
    Lee, Christopher W.
    Brand-de Wilde, Odette Manon
    Fassbinder, Eva
    Harper, R. Patrick
    Lavender, Anna
    Lockwood, George
    Malogiannis, Ioannis A.
    Ruths, Florian A.
    Schweiger, Ulrich
    Shaw, Ida A.
    Zarbock, Gerhard
    Farrell, Joan M.
    [J]. JAMA PSYCHIATRY, 2022, 79 (04) : 287 - 299
  • [10] Group schema therapy for patients with cluster-C personality disorders: A case study on avoidant personality disorder
    Bachrach, Nathan
    Arntz, Arnoud
    [J]. JOURNAL OF CLINICAL PSYCHOLOGY, 2021, 77 (05) : 1233 - 1248